- The Financing Gap That Is Burning Your Marketing Budget
- The CareCredit Problem: Why Deferred Interest Is a Minefield
- The New BNPL Entrants: Cherry, Sunbit, and Affirm HealthPay
- How Modern Financing Transforms Case Acceptance
- The Dental Financing Stack: What to Offer and Why
- Positioning Monthly Payments in Ads and Landing Pages
- The Approval Rate Shift and the 27% Production Lift
- Compliance: What the FTC and CFPB Are Watching
- Building the Financing Conversion System
If you run a cosmetic dental practice in 2026, the single most important marketing channel in your building is not Google Ads or Meta. It is the way financing gets presented during the consultation. Every $30,000 smile makeover that walks out unbooked almost never leaves because the dentistry is wrong. It leaves because the math feels wrong. And the math feels wrong because the financing conversation is built on a product — CareCredit — that patients no longer trust, sitting on a consultation sheet that has not been rewritten in a decade.
I have watched this happen in consultations across dozens of practices we work with. A patient sits down, sees the $28,000 quote for a full set of veneers, flinches, and then hears the treatment coordinator say "we offer CareCredit." The patient's face closes. Maybe they had a bad experience with deferred interest on a different purchase. Maybe their sister got hit with back interest on a crown. Either way, the conversation is over.
That same patient, shown a Cherry pre-qualification on an iPad that returns a $389 monthly payment at true 0% APR in 60 seconds, schedules their veneer prep appointment before they leave. This is not a hypothetical. According to CEOWORLD Magazine's market analysis, the patient financing market is currently valued at $22.4 billion and projected to reach $44.5 billion by 2033, with healthcare-specific BNPL growing fastest. This is the single largest consumer finance shift affecting cosmetic dental production, and most practices have not updated their playbook to match.
The Financing Gap That Is Burning Your Marketing Budget
Here is the uncomfortable math. If your practice spends $15,000 per month on Google Ads and Meta Ads to drive cosmetic consultations, and your case acceptance rate on those consultations sits at 55%, then half of what you spent on marketing is evaporating at the financing conversation. Not at the clinical exam. Not at the treatment plan. At the moment the patient hears how they are going to pay.
Practice management software provider Solutionreach has reported that roughly 63% of patients say they prefer a practice that offers payment plans, and that practices which actively present financing early in the consultation close more cases than those that hold it back until the objection phase. That gap between what patients want and what most practices actually do is where most of the revenue leak lives.
The practices growing fastest in 2026 have figured out something simple: financing is not a closing tool. It is a marketing asset. It belongs on the landing page. It belongs in the ad headline. It belongs on the intake form. By the time the patient is sitting in front of the treatment coordinator, the financing conversation should already be 80% complete. If it is not, every dollar of your ad spend is fighting against a sticker-shock objection you have not addressed.
The CareCredit Problem: Why Deferred Interest Is a Minefield
CareCredit was the default patient financing product in dentistry for twenty years for a reason. It worked. It was one of the only games in town. Practice management teams knew how to present it. Patients had heard of it. The no-interest promotional periods of 6, 12, 18, and 24 months felt generous.
The problem is the fine print that every patient eventually discovers. According to CareCredit's own published terms, if the balance is not paid in full before the promotional period ends, the full 32.99% APR is charged retroactively on the original principal from the purchase date. Not on the remaining balance. On the original balance. That is called deferred interest, and it is structurally different from a true 0% APR loan.
A patient who finances $15,000 of veneers on an 18-month CareCredit promotion, pays diligently for 17 months, and still has $800 left at month 18 does not owe 32.99% on the $800. They owe 32.99% on the entire $15,000 retroactively. That one slip-up can add $2,500+ in back interest to a case the patient thought they were paying off responsibly.
The Consumer Financial Protection Bureau has published extensive guidance on deferred interest products, and the FTC's evolving consumer protection posture in 2025-2026 has healthcare financing on its watch list. Practices that lean exclusively on CareCredit without offering transparent alternatives are taking on both brand risk and patient-experience risk.
The operational reality in 2026 is simpler than the legal nuance. Patients have learned to recognize the deferred interest trap. Younger patients especially — millennials and Gen Z who grew up watching their parents get burned — read the fine print and walk out. For cosmetic cases where the patient is paying out of pocket for an elective purchase, friction at the financing moment is fatal.
The New BNPL Entrants: Cherry, Sunbit, and Affirm HealthPay
The patient financing market opened up dramatically between 2022 and 2025. Three companies in particular have become the core of the modern dental financing stack, and each solves a different piece of the problem.
Cherry: The Elective Healthcare Specialist
Cherry was built from day one for elective healthcare. Cosmetic dentistry is one of its largest verticals alongside med spa, plastic surgery, and veterinary. According to Cherry's product documentation, the platform offers true 0% APR promotional plans (no deferred interest), soft credit pulls that do not affect patient credit scores, 60-second pre-qualification, and approval rates commonly reported around 87-90% for pre-qualified patients.
The patient experience feels like a modern checkout flow, not a subprime credit card application. The practice gets paid the full case amount within days and Cherry assumes the collection risk. For cases in the $3,000 to $25,000 range — which is most cosmetic dentistry — Cherry has become one of the default CareCredit alternatives for high-performing practices.
Sunbit: The Mid-Range Conversion Machine
Sunbit's pitch is approval rate. The company has publicly reported approval rates around 90% and some of the industry's strongest point-of-sale conversion metrics when financing is presented at the counter. Sunbit focuses on fixed monthly payments — no deferred interest, no compounding penalties, no hard credit pulls at pre-qualification. Coverage from PracticeSignal and other dental technology publications has called out Sunbit's strength on mid-range cases in the $500 to $10,000 range.
For a general cosmetic practice handling everything from whitening and bonding to partial makeovers, Sunbit is the workhorse. A patient who came in for whitening and is now considering four bonded front teeth can walk out with a financed plan in under ten minutes.
Affirm HealthPay: The Brand Recognition Play
Affirm launched Affirm HealthPay in 2025, explicitly extending its mainstream BNPL infrastructure into healthcare. Affirm is the name patients already see at checkout on Peloton, Walmart, and Amazon — which is exactly why it converts. The patient already trusts the payment experience. They do not have to learn a new brand at the moment of financial commitment.
For cases in the $10,000 to $30,000+ range — full smile makeovers, full-arch implants, aligner plus veneer combinations — Affirm's brand recognition matters disproportionately. A patient considering a $25K investment wants the financing to feel as established as the treatment. Affirm HealthPay delivers that.
The emerging playbook is not "pick one of these." It is "stack all three with CareCredit as an optional fallback." Each platform has slightly different approval criteria and case-size strengths, and offering multiple options dramatically increases the probability that any given patient gets approved for something.
How Modern Financing Transforms Case Acceptance
Case acceptance in cosmetic dentistry is the single most leverageable number in the practice. Every percentage point you move it is real production on existing patient flow.
Industry benchmarks from practice management consultants consistently place average cosmetic case acceptance between 55% and 60%. Practices that present financing clearly and early — not just as an afterthought objection response — routinely report acceptance climbing toward 70%. That is a 10 to 15 point lift, which translates directly to 15 to 25% production growth on the same new-patient volume. For deeper context on how case acceptance interacts with patient acquisition economics, see our breakdown of dental patient acquisition cost benchmarks.
The mechanism is simple. When a patient hears "$28,000 for veneers" the mental model is a total purchase they cannot afford. When they hear "$249 per month with true 0% APR" the mental model is a subscription they already manage — closer to a gym membership or a car payment than a lump-sum decision. The cognitive frame shifts from "can I afford this" to "is this worth $249 per month," which is a dramatically easier question for the patient's brain to answer in the affirmative.
This is not a financing trick. It is how elective purchasing decisions have worked since sewing machines were first sold on installment plans in the 1850s. What finally changed in 2026 is that the financing products match the patient's expectation of a modern checkout experience.
The Dental Financing Stack: What to Offer and Why
The financing stack I recommend to our cosmetic practice clients in 2026 looks like this:
The in-house tier matters more than most practice owners realize. For patients who want to finance under $2,000 — whitening, bonding, a single veneer, touch-ups — a simple three-payment in-house plan avoids third-party fees entirely. This also integrates naturally with dental membership plans, which have their own case acceptance dynamics and recurring revenue benefits.
CareCredit moves from default to fallback. That is the key structural change. Patients who specifically ask for CareCredit — usually because they have a balance elsewhere on the card or because they know they can flip the promotional period — can still use it. But the consultation no longer leads with a product that has become associated with deferred-interest surprise.
Positioning Monthly Payments in Ads and Landing Pages
If financing belongs upstream of the consultation, then financing belongs in your marketing. Here is what that looks like across the three channels that matter most.
Google Ads
The headline that converts in 2026 is the monthly payment headline. "Porcelain Veneers from $249/month — True 0% APR" consistently outperforms "Cosmetic Dentist Near You — Free Consultation." The monthly payment reframes the investment size. The "true 0% APR" language does something subtle but important: it signals to patients who have been burned by CareCredit that this is a different kind of financing. Many practices have told me their click-through rates on financing-led creative run 30 to 50% higher than on benefit-led creative, and conversion rates on the landing page climb similarly.
Pair this with call extensions, location extensions, and lead form extensions that all reinforce the financing message. The goal is for the patient to arrive at the consultation already mentally priced in monthly payment terms. For a deeper framework on structuring these campaigns, read our Google Ads for dentists guide.
Meta Ads (Facebook and Instagram)
Meta is where video financing messaging wins. A 15-second before-and-after video with a text overlay that reads "This smile: $279/month. True 0% APR. Pre-qualify in 60 seconds without affecting your credit." consistently outperforms the polished brand video that says nothing about affordability. Instagram Reels and Stories are particularly effective because the financing message feels native to how younger patients already shop.
The best-performing Meta campaigns we run layer three creative variants: a before-and-after video with monthly payment overlay, a patient testimonial that specifically mentions the payment experience, and a founder-dentist-on-camera explaining how financing works. Each speaks to a different objection state.
Landing Pages
Every cosmetic landing page should have a pre-qualification widget above the fold. Cherry, Sunbit, and Affirm all provide embeddable widgets that let the patient check their personal approved amount and monthly payment in under a minute without affecting their credit. A patient who sees their own $359/month approval before they have scheduled the consultation converts at a materially higher rate than one who hits a generic contact form.
The landing page copy should match the ad: lead with the monthly payment, explain the zero-deferred-interest structure, show a procedure-specific breakdown. Put the widget before the photos. Put the widget before the testimonials. Put the widget before the form. The pre-qualification is the conversion event, not the form submission.
The Approval Rate Shift and the 27% Production Lift
Approval rates matter because every rejected financing application is a lost case. CareCredit's approval rates have historically varied by patient credit profile, with published industry commentary from publications like Clerri noting that many younger or thin-credit-file patients struggle to get approved for the amounts cosmetic cases require. This is a silent revenue leak that practices rarely measure.
Cherry and Sunbit both report approval rates around 87 to 90% when patients pre-qualify. The numerical difference sounds modest but the compound effect is enormous. If you run 40 cosmetic consultations per month and your primary financing product approves 70% of applicants, you are financing 28 patients. A product that approves 88% of applicants finances 35 patients on the same consultation volume. At an average case value of $12,000, that delta is $84,000 in additional monthly production — over $1 million annualized — on the same marketing spend.
Layer this with the 10 to 15 point case acceptance lift that comes from presenting financing clearly and the math gets dramatic. A practice starting at 55% case acceptance that moves to 70% on the same consultation volume sees roughly a 27% production lift. That is why the financing question is a marketing question, not just a practice-management question. Patient acquisition cost only matters if the acquired patient actually closes.
Compliance: What the FTC and CFPB Are Watching
Two regulatory threads are worth understanding if you are restructuring financing in 2026.
The Consumer Financial Protection Bureau has been increasingly active on healthcare financing, with particular attention on deferred interest products and on the practice of healthcare providers steering patients toward financing without adequate disclosure. The core CFPB concern is that patients in a clinical setting are emotionally primed to agree to financing terms they would reject in a retail context. That regulatory posture is not going away, and practices that build their financing stack around transparent, non-deferred products are structurally safer.
The Federal Trade Commission's evolving rules on consumer protection — including the finalized review rule that took effect in October 2024 and broader marketing enforcement — touches financing advertising in two ways. First, any claim of "0% interest" or "no interest" in marketing must be unambiguous about whether it is true zero or deferred. Second, the treatment of testimonials about financing experiences — "I financed my veneers with no stress" — has to reflect actual typical outcomes, not cherry-picked best cases.
None of this is a reason to back away from financing marketing. It is a reason to do it cleanly. Use the "true 0% APR" language specifically when you mean true, not deferred. Disclose financing terms in the fine print that the FTC expects to see. Work with vendors (Cherry, Sunbit, Affirm) whose legal teams have already built compliant disclosure frameworks you can plug into.
Building the Financing Conversion System
Individual tactics move the needle. The compounding comes from building financing into a system that runs across every patient touchpoint. Here is what that system looks like in a high-performing cosmetic practice in 2026.
Before the consultation: financing is visible on every page of the website, in every ad, on every social post that mentions a procedure. A pre-qualification widget lives on key landing pages. The intake form asks whether the patient wants to review financing options during their visit (most say yes). An automated pre-consultation email includes a Cherry or Sunbit pre-qualification link so the patient can see their approval before they arrive.
During the consultation: the treatment coordinator leads with the monthly payment, not the total. The iPad shows the Cherry pre-qualification running live. The patient sees their actual approved amount and monthly payment within the first ten minutes of the treatment planning conversation. If the patient pre-qualified before the visit, the conversation starts from a known financing number, which shortens the decision cycle dramatically.
After the consultation: for patients who did not close same-day, a follow-up sequence reinforces the financing message. AI-driven follow-up can personalize the nudges based on the specific procedure discussed and the specific financing option presented. A patient who was quoted $28K for veneers at $389/month gets a follow-up that includes a portfolio of similar cases and a one-click return to the pre-qualification flow.
In the team training: every front-desk and treatment-coordinator team member has to be fluent in the financing conversation. Not just "we take CareCredit" but the specific distinctions between products, the true-vs-deferred-interest explanation, and the ability to reframe a price objection as a monthly payment decision in real time. This is the skill that separates a 55% close practice from a 70% close practice.
This is also where independent practices have a structural advantage over DSOs. A local cosmetic practice can retrain its two treatment coordinators on a new financing stack in a week. A DSO location has to wait for corporate rollout. For more on how independent practices exploit this kind of agility, see our piece on how independent practices beat DSO marketing budgets.
The Bottom Line
The patient financing shift from 2022 to 2026 is one of the most consequential changes in cosmetic dental economics in the last decade, and it is one of the most under-discussed. The practices that still present CareCredit as their default option are slowly bleeding case acceptance to practices that have rebuilt the financing conversation around modern BNPL products, transparent interest structures, and upstream financing messaging in ads and on landing pages.
The math is not subtle. A 10 to 15 point case acceptance lift on existing consultation volume is a 15 to 25% production increase at effectively zero additional marketing cost. A higher approval rate on financing applications means that a larger share of the patients you already pay to acquire actually close. And the compounding effect over twelve months of a well-built financing system dwarfs almost any other single operational change a cosmetic practice can make.
The question is not whether patient financing matters. It matters more than most of the things most practices spend marketing budget on. The question is whether your practice has caught up to where the market is in 2026.
If you want help rebuilding your financing stack, reworking your ad and landing page messaging around monthly payments, and training your team to convert at the modern 70% rate rather than the legacy 55% rate, explore our dental marketing services or book a strategy call. You can also review our case studies to see what this looks like in practice. And for broader context on where cosmetic demand is heading, read our analysis of the cosmetic dentistry market in 2026.